


## Telratolimod

<b>Cat. No.:</b>	HY-109104		
<b>CAS No.:</b>	1359993-59-1		
<b>Molecular Formula:</b>	C <sub>36</sub> H <sub>59</sub> N <sub>5</sub> O <sub>2</sub>		
<b>Molecular Weight:</b>	593.89		
<b>Target:</b>	Toll-like Receptor (TLR)		
<b>Pathway:</b>	Immunology/Inflammation		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 62.5 mg/mL (105.24 mM; Need ultrasonic)  
 Ethanol : 50 mg/mL (84.19 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	1.6838 mL	8.4191 mL	16.8381 mL
	5 mM	0.3368 mL	1.6838 mL	3.3676 mL
	10 mM	0.1684 mL	0.8419 mL	1.6838 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% EtOH >> 90% corn oil  
Solubility: ≥ 2.5 mg/mL (4.21 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: 2.08 mg/mL (3.50 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: 2.08 mg/mL (3.50 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.08 mg/mL (3.50 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

Telratolimod (MEDI9197) is a potent toll like receptors 7/8 (TLR7/8) agonist, with antitumor activity<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

TLR7	TLR8
------	------

---

<b>In Vitro</b>	Telratolimod (3M-052) is a toll like receptors 7/8 (TLR7/8) agonist, with antitumor activity <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	Telratolimod (50 µg) inhibits the tumor volume, and more potently blocks tumor growth in combination with CpG ODN in BALB/c mice bearing CT26 colon carcinoma cells. Telratolimod (100 µg) plus 200 µg of CpG ODN slows tumor growth and prolongs survival of mice bearing large tumors <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## CUSTOMER VALIDATION

- ACS Cent Sci. October 7, 2022.
- ACS Nano. 2022 Aug 3.
- Adv Sci (Weinh). 2022 Dec 16;e2206001.
- JCI Insight. 2022 May 17;e146608.
- Biochem Bioph Res Co. 2023 Feb 16.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

---

## REFERENCES

[1]. Zhao BG, et al. Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors. J Immunother Cancer. 2014 May 13;2:12.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA